Detalles de la búsqueda
1.
Immune checkpoint inhibitors in patients aged 80 or older with advanced non-small cell lung cancer or melanoma: a real-life multicentre study.
Acta Oncol
; 61(11): 1339-1346, 2022 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-36239950
2.
Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial.
Lancet Oncol
; 21(9): 1224-1233, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32888454
3.
Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT).
Lancet
; 387(10026): 1415-1426, 2016 Apr 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-26777916
4.
Outcome of Patients With Resected Early-Stage Non-small Cell Lung Cancer and EGFR Mutations: Results From the IFCT Biomarkers France Study.
Clin Lung Cancer
; 24(1): 1-10, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36180314
5.
Long-term effectiveness and treatment sequences in patients with extensive stage small cell lung cancer receiving atezolizumab plus chemotherapy: Results of the IFCT-1905 CLINATEZO real-world study.
Lung Cancer
; 185: 107379, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37757576
6.
Management of patients with synchronous head-and-neck and lung cancers: SYNCHRON GFPC 15-01 study.
J Cancer Res Ther
; 18(Supplement): S160-S164, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-36510958
7.
Impact of KRAS G12C mutation in patients with advanced non-squamous non-small cell lung cancer treated with first-line pembrolizumab monotherapy.
Lung Cancer
; 174: 45-49, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-36323057
8.
Brief Report on the Efficacy of Nivolumab in Patients With Previously Treated Advanced Large-Cell Neuroendocrine Cancer of the Lung.
JTO Clin Res Rep
; 2(4): 100129, 2021 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-34590004
9.
Multicenter phase II trial of nintedanib plus docetaxel in second-line treatment in advanced non-squamous non-small cell lung cancer patients refractory to first-line platin-based chemotherapy (REFRACT GFPC 02-15 study).
Lung Cancer
; 161: 122-127, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34583220
10.
Phase III randomized study of carboplatin pemetrexed with or without bevacizumab with initial versus "at progression" cerebral radiotherapy in advanced non squamous non-small cell lung cancer with asymptomatic brain metastasis.
Ther Adv Med Oncol
; 13: 17588359211006983, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33948123
11.
Impact of Programmed Death Ligand 1 Expression in Advanced Non-Small-Cell Lung Cancer Patients, Treated by Chemotherapy (GFPC 06-2015 Study).
Onco Targets Ther
; 13: 13299-13305, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-33408480
12.
Duration of nivolumab for pretreated, advanced non-small-cell lung cancer.
Cancer Med
; 9(19): 6923-6932, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32412157
13.
Management and outcomes of non-small cell lung cancer patients with rapid progression under second-or-more-line immune checkpoint inhibitors: ERORECI study (GFPC 2016-04).
Cancer Med
; 9(2): 432-439, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31747137
14.
Efficacy and safety of programmed cell-death-protein-1 and its ligand inhibitors in pretreated patients with epidermal growth-factor receptor-mutated or anaplastic lymphoma kinase-translocated lung adenocarcinoma.
Medicine (Baltimore)
; 99(3): e18726, 2020 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-32011450
15.
First-line pembrolizumab for non-small cell lung cancer patients with PD-L1 ≥50% in a multicenter real-life cohort: The PEMBREIZH study.
Cancer Med
; 9(7): 2309-2316, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32022459
16.
Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients With Advanced NSCLC With BRAF, HER2, or MET Mutations or RET Translocation: GFPC 01-2018.
J Thorac Oncol
; 15(4): 628-636, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-31945494
17.
PD-L1-expression patterns in large-cell neuroendocrine carcinoma of the lung: potential implications for use of immunotherapy in these patients: the GFPC 03-2017 "EPNEC" study.
Ther Adv Med Oncol
; 12: 1758835920937972, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32684990
18.
Real-Life Efficacy of Osimertinib in Pretreated Octogenarian Patients with T790M-Mutated Advanced Non-small Cell Lung Cancer.
Target Oncol
; 14(3): 307-314, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-31119481
19.
Octogenarians with EGFR-mutated non-small cell lung cancer treated by tyrosine-kinase inhibitor: a multicentric real-world study assessing tolerance and efficacy (OCTOMUT study).
Oncotarget
; 9(9): 8253-8262, 2018 Feb 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-29492192
20.
Clinicopathological characteristics of ROS1- and RET-rearranged NSCLC in caucasian patients: Data from a cohort of 713 non-squamous NSCLC lacking KRAS/EGFR/HER2/BRAF/PIK3CA/ALK alterations.
Oncotarget
; 8(32): 53336-53351, 2017 Aug 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-28881815